Katharine Andress Rowe Price

Dr. Katharine Andress Rowe Price

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2012 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
KPKatharine Andress Rowe Price
Katharine Andress Rowe Price
ECEzra E. Cohen
Ezra E. Cohen

1 April 2014 in Oral Oncology
Verified
Journal Article
Closed access
JGJessica L. Geiger
Jessica L. Geiger
ALAhmed F. Lazim
Ahmed F. Lazim
FWFrancis J. Walsh
Francis J. Walsh
RFRobert L. Foote
Robert L. Foote
EMEric J. Moore
Eric J. Moore
KPKatharine Andress Rowe Price
Katharine Andress Rowe Price


1 May 2016 in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Verified
Journal Article
Closed access
ACAshish V. Chintakuntlawar
Ashish V. Chintakuntlawar
WSWonwoo Shon
Wonwoo Shon
MEMichele Erickson-Johnson
Michele Erickson-Johnson
EBElizabeth Bilodeau
Elizabeth Bilodeau
SJSarah M. Jenkins
Sarah M. Jenkins
JGJoaquín J. García
Joaquín J. García

5 June 2022 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
KPKatharine Andress Rowe Price
Katharine Andress Rowe Price
KAKathryn M. Van Abel
Kathryn M. Van Abel
EMEric J. Moore
Eric J. Moore
SPSamir H. Patel
Samir H. Patel
MHMichael L. Hinni
Michael L. Hinni
DMDaniel Ma
Daniel Ma
Patients with human papillomavirus oropharyngeal cancer are highly curable but risk significant long-term toxic effects with standard therapy. This study investigated a de-escalation strategy of decreased adjuvant radiation therapy and chemotherapy after transoral robotic surgery, and reports on long-term functional and quality of life (QOL) outcomes. Eligible patients had a p16-positive oropharyngeal cancer and ≤10 pack-year smoking history and underwent surgery followed by treatment with either 30 Gy delivered in 1.5-Gy fractions twice per day over 2 weeks with weekly docetaxel (15 mg/m2) if they had intermediate pathologic risk factors or 36 Gy in 1.8-Gy fractions twice per day over 2 weeks with the same chemotherapy if they had extranodal extension. Toxic effects, swallow function, and QOL were measured longitudinally. Seventy-nine patients (89.9% male) were treated and eligible for toxic effect and functional evaluation. Dry mouth was the most common grade 1 toxic effect at 1 year (55.6%), 2 years (53.3%), and 3 years (49.2%). The cumulative rates of grade 2 toxic effects at 1, 2, and 3 years were 1.4%, 6.7%, and 6.8%, respectively. There were only 2 grade 3 toxic effects at ≥1 year, including a grade 3 fatigue at 2.5 years, and a grade 3 superficial soft tissue fibrosis at 4 years. There were no grade 4 to 5 toxic effects. No patients were percutaneous endoscopic gastrostomy-dependent. Swallow function improved by 12 months posttreatment. QOL improved over time by all measurement tools and most patients returned to baseline level of function and QOL. De-escalated adjuvant therapy for select patients with human papillomavirus oropharyngeal cancer resulted in low rates of long-term toxic effects, excellent swallow outcomes, and preservation of global and xerostomia-related QOL.

29 April 2020 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
KCKyriakos Chatzopoulos
Kyriakos Chatzopoulos
ACAndrea R. Collins
Andrea R. Collins
SSSotiris Sotiriou
Sotiris Sotiriou
MKMichael G. Keeney
Michael G. Keeney
DVDaniel W. Visscher
Daniel W. Visscher
JGJoaquin J. Garcia
Joaquin J. Garcia